HALO News and Press, Halozyme Therapeutics Inc. From 01/10/22

HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK - 2022 Revenue Guidance of $530 to $560 Million Representing 23-26% Growth over Expected 2021 Revenue - - 2022 Recurring Revenue from Royalties Projected to Grow by Approximately 50% over Record Royalties in 2021 to Appro...

Halozyme to Present Virtually at the 40th Annual J.P. Morgan Health Care Conference PR Newswire SAN DIEGO , Jan. 4, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley , president and chief execut...

The U.S. equity market breathed a sigh of relief on Dec. 16 after the U.S. Federal Reserve disclosed its plans for reduced monthly bond-buying and increased interest rates for 2022. The central bank's aggressive stance on managing the stickier-than-expected inflation can prove to be a ...

Gainers: Petros Pharmaceuticals (NASDAQ:PTPI) +37%, Biofrontera BFRI +20%, ABVC BioPharma (NASDAQ:ABVC) +12%, Halozyme Therapeutics (NASDAQ:HALO) +11%, Context Therapeutics CNTX +9%. Losers: Angion Biomedica (NASDAQ:ANGN) -22%, Ensysce Biosciences ...

Halozyme Therapeutics (NASDAQ:HALO) has announced a new share repurchase program to buyback up to $750M of its outstanding common stock over the next three years. The program follows the recent completion of the company's previous $550M three-year share repurchase program. The biopharmaceutic...

HALOZYME ANNOUNCES $750 MILLION THREE-YEAR SHARE REPURCHASE PROGRAM - Company Plans to Purchase up to $250 Million Worth of Shares by the End of 2022 Starting with Entering into a $150 Million Accelerated Share Repurchase Program Transaction in the Coming Week - - New Share ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With its latest variant (Omicron) spreading, it seems Covid-19 will continue to play a major role in world events in 2022, just like it did in 2020, and in 2021. With this, pandemic-related drug stocks will likely remain ho...

The financial performance of HALO is growing at an extremely high rate, and this dynamic is expected to continue until at least 2027. The company's market prospects are undeniable, with more than 79 drugs approved by the FDA, and the company continues to negotiate agreements and penet...

Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse - Approval marks the ninth indication for DA...

The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Halozyme Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation